2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.31 Liu

PP01.31 Liu - Poster

Pdf Summary

Liquid biopsy using plasma circulating tumor DNA (ctDNA) is gaining popularity for identifying actionable oncogenic drivers like the KRAS mutations in non-small-cell lung cancer (NSCLC). The study focused on profiling clinical characteristics of KRAS G12D mutant NSCLC using ctDNA sequencing. Results showed that out of 230 advanced NSCLC patients with KRAS mutations, KRAS G12C was the predominant subtype, followed by KRAS G12D. KRAS G12D mutations were significantly more common in never smokers. Despite a smaller sample size, never smokers tended to have shorter overall survival compared to smokers. Plasma ctDNA analysis had a quicker turnaround time compared to tissue sequencing. First-line immunotherapy or chemoimmunotherapy showed poor outcomes, emphasizing the need for targeted therapy for KRAS G12D. The study highlights the potential of plasma ctDNA analysis in identifying KRAS G12D mutant NSCLC, particularly in never smokers, and the urgency for more effective targeted therapy. Further research is needed to explore the prognostic and predictive implications of plasma ctDNA in guiding targeted therapy for metastatic NSCLC with HER2 mutations.

Keywords

liquid biopsy

plasma ctDNA

KRAS mutations

non-small-cell lung cancer

NSCLC

KRAS G12D

ctDNA sequencing

never smokers

targeted therapy

metastatic NSCLC